HZ Q1060
Alternative Names: HZ-Q1060Latest Information Update: 30 Jan 2023
At a glance
- Originator Hangzhou HealZen Therapeutics
- Class Antineoplastics
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer